Literature DB >> 25782066

4th international conference on tumor progression and therapeutic resistance: meeting report.

Varun V Prabhu1, Wafik S El-Deiry.   

Abstract

The fourth international conference on tumor progression and therapeutic resistance organized in association with GTCbio was held in Boston, MA from March 9 to 11, 2014. The meeting attracted a diverse group of experts in the field of cancer biology, therapeutics and medical oncology from academia and industry. The meeting addressed the current challenges in the treatment of cancer including tumor heterogeneity, therapy resistance and metastasis along with the need for improved biomarkers of tumor progression and clinical trial design. Keynote speakers included Clifton Leaf, Editor at Fortune Magazine, Dr. Mina Bissell from the Lawrence Berkeley National Laboratory and Dr. Levi Garraway from the Dana Farber Cancer Institute. The meeting featured cutting edge tools, preclinical models and the latest basic, translational and clinical research findings in the field.

Entities:  

Keywords:  cancer stem cell; cancer therapy; driver mutation; metastasis; therapeutic resistance; translational medicine; tumor heterogeneity; tumor microenvironment; tumor progression

Mesh:

Year:  2015        PMID: 25782066      PMCID: PMC4622493          DOI: 10.1080/15384047.2015.1004928

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  89 in total

1.  Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.

Authors:  Michael Dews; Asal Homayouni; Duonan Yu; Danielle Murphy; Cinzia Sevignani; Erik Wentzel; Emma E Furth; William M Lee; Greg H Enders; Joshua T Mendell; Andrei Thomas-Tikhonenko
Journal:  Nat Genet       Date:  2006-07-30       Impact factor: 38.330

2.  Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.

Authors:  M Tamura; J Gu; K Matsumoto; S Aota; R Parsons; K M Yamada
Journal:  Science       Date:  1998-06-05       Impact factor: 47.728

3.  Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA.

Authors:  A Janz; C Sevignani; K Kenyon; C V Ngo; A Thomas-Tikhonenko
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

4.  Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.

Authors:  Wenge Wang; Seok-Hyun Kim; Wafik S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

5.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 6.  Normal human melanocyte homeostasis as a paradigm for understanding melanoma.

Authors:  Nikolas K Haass; Meenhard Herlyn
Journal:  J Investig Dermatol Symp Proc       Date:  2005-11

Review 7.  The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth.

Authors:  Diane R Fels; Constantinos Koumenis
Journal:  Cancer Biol Ther       Date:  2006-07-01       Impact factor: 4.742

8.  The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells.

Authors:  Catherine Huang; Xiang M Zhang; Raluca T Tavaluc; Lori S Hart; David T Dicker; Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2009-11-27       Impact factor: 4.742

9.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.

Authors:  R Dalla-Favera; M Bregni; J Erikson; D Patterson; R C Gallo; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.

Authors:  V M Weaver; O W Petersen; F Wang; C A Larabell; P Briand; C Damsky; M J Bissell
Journal:  J Cell Biol       Date:  1997-04-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.